 |
2008 Press Releases
June 2, 2008 - Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase I and Phase II Data at ASCO 2008 Annual Meeting
Read » | PDF »
May 22, 2008 - Cougar Biotechnology to Present Clinical Data on CB7630 (Abiraterone Acetate) at American Society of Clinical Oncology 2008 Annual Meeting
Read » | PDF »
May 12, 2008 - Cougar Biotechnology Announces First Quarter 2008 Financial Results
Read » | PDF »
May 5, 2008 - Cougar Biotechnology to Present at the Leerink Swann Cancer Roundtable Conference
Read » | PDF »
April 29, 2008 - Cougar Biotechnology Announces Initiation of Phase III Trial of CB7630 (Abiraterone Acetate)
Read » | PDF »
April 1, 2008 - Cougar Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III trial of CB7630 (Abiraterone Acetate)
Read » | PDF »
- March 31, 2008 - Cougar Biotechnology Announces 2007 Fourth Quarter and Year-End Financial Results
Read » | PDF »
- March 11, 2008 - Cougar Biotechnology to Present at Cowen and Company 28th Annual Health Care Conference
Read » | PDF »
- February 15, 2008 - Cougar Biotechnology Announces Presentation of Positive CB7630 Phase I Clinical Data at ASCO 2008 Genitourinary Cancers Symposium
Read » | PDF »
- February 14, 2008 - Cougar Biotechnology Presents Positive CB7630 Phase I and Phase II Data at ASCO 2008 Genitourinary Cancers Symposium
Read » | PDF »
- January 30, 2008 - Cougar Biotechnology to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Read » | PDF »
| | |
Cougar Biotechnology, Inc.
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(310) 943-8040 Main
(310) 943-8059 Fax |
